Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Positron-Emission Tomography | 16 | 2026 | 177 | 4.220 |
Why?
|
| Radiopharmaceuticals | 9 | 2024 | 103 | 2.130 |
Why?
|
| Brain | 12 | 2026 | 1032 | 2.060 |
Why?
|
| Microtubules | 3 | 2025 | 22 | 1.660 |
Why?
|
| Glioblastoma | 5 | 2017 | 161 | 1.590 |
Why?
|
| Fluorine Radioisotopes | 4 | 2018 | 22 | 1.160 |
Why?
|
| Brain Neoplasms | 5 | 2017 | 649 | 1.120 |
Why?
|
| Tissue Distribution | 8 | 2024 | 74 | 1.000 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 14 | 0.920 |
Why?
|
| Insulin | 2 | 2025 | 394 | 0.900 |
Why?
|
| Animals | 23 | 2026 | 8579 | 0.880 |
Why?
|
| Administration, Intranasal | 2 | 2025 | 36 | 0.880 |
Why?
|
| Carbon Radioisotopes | 5 | 2019 | 24 | 0.780 |
Why?
|
| Mice | 11 | 2022 | 2720 | 0.730 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 140 | 0.720 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 170 | 0.670 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 140 | 0.670 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 84 | 0.620 |
Why?
|
| Neoplasms | 4 | 2019 | 793 | 0.620 |
Why?
|
| Isotope Labeling | 4 | 2019 | 17 | 0.600 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 91 | 0.580 |
Why?
|
| Piperidines | 1 | 2019 | 141 | 0.570 |
Why?
|
| Cell Line, Tumor | 8 | 2019 | 781 | 0.520 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 2 | 0.520 |
Why?
|
| Nicotine | 1 | 2019 | 179 | 0.520 |
Why?
|
| Radioligand Assay | 1 | 2017 | 26 | 0.520 |
Why?
|
| Benzopyrans | 1 | 2017 | 7 | 0.510 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 58 | 0.510 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 112 | 0.510 |
Why?
|
| Boron Compounds | 1 | 2017 | 11 | 0.510 |
Why?
|
| Neuroblastoma | 1 | 2017 | 32 | 0.500 |
Why?
|
| Pyrroles | 1 | 2017 | 62 | 0.500 |
Why?
|
| Pyrimidines | 1 | 2017 | 80 | 0.490 |
Why?
|
| Alzheimer Disease | 3 | 2025 | 295 | 0.480 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 98 | 0.480 |
Why?
|
| Blood-Brain Barrier | 4 | 2019 | 52 | 0.440 |
Why?
|
| Ligands | 5 | 2022 | 97 | 0.440 |
Why?
|
| Humans | 23 | 2025 | 34562 | 0.430 |
Why?
|
| Methadyl Acetate | 1 | 2014 | 1 | 0.430 |
Why?
|
| Molecular Structure | 5 | 2019 | 60 | 0.400 |
Why?
|
| Tyrosine | 1 | 2013 | 28 | 0.390 |
Why?
|
| Alanine | 1 | 2013 | 30 | 0.390 |
Why?
|
| Triazoles | 1 | 2013 | 16 | 0.390 |
Why?
|
| Molecular Probes | 1 | 2013 | 16 | 0.380 |
Why?
|
| Butyrates | 1 | 2012 | 4 | 0.380 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 10 | 0.380 |
Why?
|
| Alpha Particles | 3 | 2017 | 7 | 0.370 |
Why?
|
| PPAR alpha | 1 | 2012 | 29 | 0.370 |
Why?
|
| Glioma | 1 | 2013 | 138 | 0.360 |
Why?
|
| Male | 16 | 2026 | 20740 | 0.350 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 88 | 0.310 |
Why?
|
| Ketones | 1 | 2008 | 11 | 0.280 |
Why?
|
| Amides | 1 | 2008 | 30 | 0.280 |
Why?
|
| Mesylates | 1 | 2007 | 2 | 0.270 |
Why?
|
| Acetanilides | 1 | 2007 | 13 | 0.270 |
Why?
|
| Receptors, Opioid | 1 | 2026 | 15 | 0.250 |
Why?
|
| Glucosides | 1 | 2025 | 13 | 0.230 |
Why?
|
| Benzhydryl Compounds | 1 | 2025 | 23 | 0.230 |
Why?
|
| Alcoholism | 1 | 2026 | 104 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 203 | 0.220 |
Why?
|
| Thrombectomy | 1 | 2025 | 75 | 0.210 |
Why?
|
| Gallium Radioisotopes | 1 | 2024 | 3 | 0.210 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2024 | 7 | 0.210 |
Why?
|
| Heterocyclic Compounds | 1 | 2024 | 16 | 0.210 |
Why?
|
| Cations | 3 | 2008 | 10 | 0.210 |
Why?
|
| Alcohol Drinking | 1 | 2026 | 261 | 0.200 |
Why?
|
| Rodentia | 1 | 2022 | 10 | 0.190 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 21 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2025 | 1393 | 0.190 |
Why?
|
| Doxorubicin | 1 | 2022 | 92 | 0.180 |
Why?
|
| Primates | 1 | 2022 | 130 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2022 | 755 | 0.180 |
Why?
|
| Receptors, Dopamine D3 | 2 | 2022 | 33 | 0.180 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 174 | 0.180 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2022 | 82 | 0.170 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2019 | 10 | 0.170 |
Why?
|
| Macaca | 1 | 2020 | 30 | 0.170 |
Why?
|
| Actinium | 2 | 2017 | 3 | 0.170 |
Why?
|
| Capillary Permeability | 2 | 2017 | 18 | 0.160 |
Why?
|
| Female | 6 | 2026 | 21532 | 0.160 |
Why?
|
| Rats | 2 | 2022 | 1946 | 0.160 |
Why?
|
| Papio | 1 | 2020 | 94 | 0.160 |
Why?
|
| Neurotransmitter Agents | 1 | 2019 | 35 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2008 | 96 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 7 | 0.150 |
Why?
|
| Diet, Mediterranean | 1 | 2019 | 32 | 0.150 |
Why?
|
| Niacinamide | 1 | 2019 | 8 | 0.150 |
Why?
|
| Zirconium | 1 | 2018 | 2 | 0.150 |
Why?
|
| Chlorides | 1 | 2018 | 13 | 0.150 |
Why?
|
| Radioisotopes | 1 | 2018 | 8 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2018 | 11 | 0.140 |
Why?
|
| Cocaine | 1 | 2022 | 355 | 0.140 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 90 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 182 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 104 | 0.140 |
Why?
|
| Cyclization | 2 | 2008 | 3 | 0.140 |
Why?
|
| Argininosuccinate Synthase | 1 | 2018 | 2 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2019 | 633 | 0.140 |
Why?
|
| Electrochemistry | 2 | 2008 | 17 | 0.140 |
Why?
|
| Arginine | 1 | 2018 | 23 | 0.140 |
Why?
|
| Models, Biological | 2 | 2018 | 432 | 0.130 |
Why?
|
| Amino Acids | 1 | 2018 | 54 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2017 | 485 | 0.130 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2017 | 8 | 0.130 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2017 | 12 | 0.130 |
Why?
|
| Biological Transport | 1 | 2017 | 76 | 0.130 |
Why?
|
| Urea | 1 | 2017 | 39 | 0.130 |
Why?
|
| Quinolines | 1 | 2017 | 29 | 0.130 |
Why?
|
| Liposomes | 1 | 2017 | 34 | 0.130 |
Why?
|
| Substrate Specificity | 1 | 2017 | 91 | 0.130 |
Why?
|
| Sarcoma | 1 | 2018 | 94 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2017 | 21 | 0.130 |
Why?
|
| Ethylamines | 1 | 2016 | 3 | 0.130 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2016 | 7 | 0.130 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2016 | 8 | 0.130 |
Why?
|
| DNA Damage | 1 | 2017 | 97 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 57 | 0.130 |
Why?
|
| Cell Communication | 1 | 2017 | 42 | 0.130 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 23 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2019 | 430 | 0.120 |
Why?
|
| Protein Binding | 1 | 2017 | 255 | 0.120 |
Why?
|
| Pericytes | 1 | 2016 | 32 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2017 | 94 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 279 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 229 | 0.110 |
Why?
|
| Liver | 1 | 2017 | 513 | 0.100 |
Why?
|
| Cognition | 1 | 2017 | 576 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 30 | 0.100 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 19 | 0.100 |
Why?
|
| Self Administration | 2 | 2026 | 386 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2013 | 86 | 0.100 |
Why?
|
| Kidney | 1 | 2017 | 528 | 0.100 |
Why?
|
| Obesity | 1 | 2020 | 1246 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 271 | 0.090 |
Why?
|
| Ethanol | 2 | 2026 | 199 | 0.090 |
Why?
|
| Middle Aged | 3 | 2025 | 12726 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 575 | 0.090 |
Why?
|
| Stereoisomerism | 2 | 2008 | 28 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 614 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 823 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 628 | 0.070 |
Why?
|
| Macaca mulatta | 2 | 2022 | 355 | 0.070 |
Why?
|
| Benzilates | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mandelic Acids | 1 | 2008 | 2 | 0.070 |
Why?
|
| Hydroxylation | 1 | 2008 | 5 | 0.070 |
Why?
|
| Fluorenes | 1 | 2008 | 4 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2026 | 1129 | 0.070 |
Why?
|
| Indoles | 1 | 2008 | 67 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 36 | 0.070 |
Why?
|
| Quinolones | 1 | 2007 | 8 | 0.070 |
Why?
|
| Reference Standards | 1 | 2007 | 34 | 0.070 |
Why?
|
| Salts | 1 | 2007 | 1 | 0.070 |
Why?
|
| Imines | 1 | 2007 | 2 | 0.070 |
Why?
|
| Electrons | 1 | 2007 | 12 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 988 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2025 | 3623 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 120 | 0.060 |
Why?
|
| Adult | 1 | 2019 | 10030 | 0.060 |
Why?
|
| Aged | 3 | 2025 | 11022 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 1 | 2025 | 18 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 51 | 0.060 |
Why?
|
| Macaca fascicularis | 1 | 2026 | 549 | 0.050 |
Why?
|
| Sex Factors | 1 | 2026 | 708 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 803 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2025 | 597 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 939 | 0.050 |
Why?
|
| Protein Transport | 1 | 2020 | 82 | 0.040 |
Why?
|
| Eating | 1 | 2020 | 81 | 0.040 |
Why?
|
| Ketone Bodies | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 100 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2019 | 49 | 0.040 |
Why?
|
| Radiochemistry | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 104 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 325 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 120 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 96 | 0.040 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2018 | 1 | 0.030 |
Why?
|
| Hydrolases | 1 | 2018 | 5 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 476 | 0.030 |
Why?
|
| Quinazolines | 1 | 2018 | 40 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 67 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2018 | 111 | 0.030 |
Why?
|
| Memory | 1 | 2019 | 216 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 585 | 0.030 |
Why?
|
| Cysteamine | 1 | 2017 | 2 | 0.030 |
Why?
|
| Copper Radioisotopes | 1 | 2017 | 3 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 16 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 45 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 74 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 4157 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 232 | 0.030 |
Why?
|
| Antigens | 1 | 2016 | 36 | 0.030 |
Why?
|
| Peptides | 1 | 2017 | 143 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 71 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2016 | 37 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2025 | 3825 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 87 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 923 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 208 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 93 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 363 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 118 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 296 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 182 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 657 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 110 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 842 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 2353 | 0.020 |
Why?
|
| Phenol | 1 | 2007 | 11 | 0.020 |
Why?
|
Solingapuram Sai's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(209)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(49)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_